🟢 Ionis Pharmaceuticals is trading 5% up in pre-market after FDA approves GSK’s hepatitis B treatment

Ionis Pharmaceuticals is trading at $46.70, up 5.49%, after partner GSK received FDA approval for Hibsago (bepirovirsen), a first-in-class treatment for chronic hepatitis B. - Ionis discovered the medicine and partnered with GSK on its development; the approval is a significant company-specific catalyst. - The FDA approval was announced October 20 and reported October 21. - Broader biotech strength may also support the move, though major U.S. indices are lower pre-market.